+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants



Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants



Plos One 5(3): E9467



Intermittent preventive treatment in infants (IPTi) is a new malaria control tool. However, it is uncertain whether IPTi works mainly through chemoprophylaxis or treatment of existing infections. Understanding the mechanism is essential for development of replacements for sulfadoxine-pyrimethamine (SP) where it is no longer effective. This study investigated how protection against malaria given by SP, chlorproguanil-dapsone (CD) and mefloquine (MQ), varied with time since administration of IPTi. A secondary analysis of data from a randomised, placebo-controlled trial in an area of high antifolate resistance in Tanzania was conducted. IPTi using SP, CD, MQ or placebo was given to 1280 infants at 2, 3 and 9 months of age. Poisson regression with random effects to adjust for potential clustering of malaria episodes within children was used to calculate incidence rate ratios for clinical malaria in defined time strata following IPTi. The short-acting antimalarial CD gave no protection against clinical malaria, whereas long-acting MQ gave two months of substantial protection (protective efficacy (PE) 73.1% (95% CI: 23.9, 90.5) and 73.3% (95% CI: 0, 92.9) in the first and second month respectively). SP gave some protection in the first month after treatment (PE 64.5% (95% CI: 10.6, 85.9)) although it did not reduce the incidence of malaria up to 12 months of age. There was no evidence of either long-term protection or increased risk of malaria for any of the regimens. Post-treatment chemoprophylaxis appears to be the main mechanism by which IPTi protects children against malaria. Long-acting antimalarials are therefore likely to be the most effective drugs for IPTi, but as monotherapies could be vulnerable to development of drug resistance. Due to concerns about tolerability, the mefloquine formulation used in this study is not suitable for IPTi. Further investigation of combinations of long-acting antimalarials for IPTi is needed. Clinicaltrials.gov NCT00158574.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052731213

Download citation: RISBibTeXText

PMID: 20209126


Related references

Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. Plos One 3(5): E2227, 2008

Intermittent preventive malaria treatment in Tanzanian infants. Lancet 366(9485): 545; Author Reply 545-6, 2005

Intermittent preventive treatment for malaria and anaemia control in Tanzanian infants; the development and implementation of a public health strategy. Transactions of the Royal Society of Tropical Medicine and Hygiene 103(1): 79-86, 2008

Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants?. Malaria Journal 7: 54, 2008

Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 374(9700): 1521-1532, 2009

The risk of malaria in Ghanaian infants born to women managed in pregnancy with intermittent screening and treatment for malaria or intermittent preventive treatment with sulfadoxine/pyrimethamine. Malaria Journal 15: 46, 2016

Intermittent preventive treatment of infants with mefloquine reduces risk of clinical malaria in areas of moderate malaria transmission and high resistance to sulphadoxine-pyrimethamine, but safety and tolerability issues need consideration. Evidence-Based Medicine 15(3): 71-72, 2010

Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365(9469): 1481-1483, 2005

Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women. Cochrane Database of Systematic Reviews 2011(10): Cd006689, 2011

Intermittent Screening and Treatment or Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine Versus Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine for the Control of Malaria During Pregnancy in Western Kenya. Obstetric Anesthesia Digest 36(4): 211-212, 2016

Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet 386(10012): 2507-2519, 2016

Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357(9267): 1471-1477, 2001

Intermittent preventive treatment against malaria in infants in Gabon. 2007

Review of intermittent preventive treatment for malaria in infants and children. Journal of Paediatrics and Child Health 43(6): 424-428, 2007

Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. Plos Medicine 8(2): E1000407, 2011